373例乙型肝炎患者HBV-DNA定量与乙型肝炎病毒核心抗原及肝脏酶学指标的相关性分析(3)
 |
| 第1页 |
参见附件。
[3] Lu FM，Zhuang H. Management of hepatitis B in China[J]. Chin Med J (Engl)，2009，122(1)：3-4.
[4] Mommeja-Marin H，Mondou E，Blum MR，et al. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection：analysis and review of the literature[J]. Hepatology，2003，37(6)：1309-1319.
[5] Stramer SL，Krysztof DE，Brodsky JP，et al. Sensitivity comparison of two Food and Drug Administration-licensed，triplex nucleic acid test automated assays for hepatitis B virus DNA detection and associated projections of United States yield[J]. Transfusion，2011，51(9)：2012-2022.
[6] Cho EY，Choi CS，Cho JH，et al. Association between Hepatitis B Virus X Gene Mutations and Clinical Status in Patients with Chronic Hepatitis B Infection[J]. Gut Liver，2011，5(1)：70-76.
[7] Chu CM，Yeh CT，Lee CS，et al. Precore stop mutant in HBeAg-positive patients with chronic hepatitis B：clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion[J]. J Clin Microbiol，2002，40(1)：16-21.
[8] Shinkai N，Tanaka Y，Ito K，et al. Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2[J]. J Clin Microbiol，2007，45(10)：3191-3197.
[9] Witjes CD，IJzermans JN，Vander Eijk AA，et al. Quantitative HBV DNA and AST are strong predictors for survival after HCC detection in chronic HBV patients[J]. Neth J Med，2011，69(11)：508-513.
(收稿日期：2012-04-19 本文编辑：郭静娟)
您现在查看是摘要介绍页，详见PDF附件(3070kb)。